Oncology and Hematology - Global Oncology Academy

337-352 of 790

Recognizing the Burden of Paroxysmal Nocturnal Hemoglobinuria
Recognizing the Burden of Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®
Recognizing the Burden of Paroxysmal Nocturnal Hemoglobinuria
Brian P. McDonough, MD, FAAFP
- Brian P. McDonough, MD, FAAFP
Conquering the Burden & Impacts of PNH
Conquering the Burden & Impacts of PNH
Project Oncology®
Conquering the Burden & Impacts of PNH
Charles Turck, PharmD, BCPS, BCCCP; Hana Safah, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Hana Safah, MD
- Timothy Kubal, MD
Managing PNH: Clinical Considerations
Managing PNH: Clinical Considerations
Project Oncology®
Managing PNH: Clinical Considerations
Charles Turck, PharmD, BCPS, BCCCP; Jamie Koprivnikar, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Jamie Koprivnikar, MD
- Abdulraheem Yacoub, MD
Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®
Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Brian P. McDonough, MD, FAAFP
- Brian P. McDonough, MD, FAAFP
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart Matters
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Jun-ichi Abe
- Jun-ichi Abe
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Project Oncology®
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Ryan Quigley
- Ryan Quigley
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Project Oncology®
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Project Oncology®
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
MinuteCE®
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Joyce F. Liu, MD, MPH; Kathleen N. Moore, MD
0.50 program credits
- Joyce F. Liu, MD, MPH
- Kathleen N. Moore, MD
0.50 program credits
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MinuteCE®
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Joyce F. Liu, MD, MPH
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
MinuteCE®
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Kathleen N. Moore, MD
0.50 program credits
- Kathleen N. Moore, MD
0.50 program credits
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
MinuteCE®
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Joyce F. Liu, MD, MPH
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
MinuteCE®
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Joyce F. Liu, MD, MPH
0.50 credits 5 episodes
- Kathleen N. Moore, MD
- Joyce F. Liu, MD, MPH
0.50 credits 5 episodes
MOA: CDH6-Targeted Antibody-Drug Conjugates
MOA: CDH6-Targeted Antibody-Drug Conjugates
MinuteCE®
MOA: CDH6-Targeted Antibody-Drug Conjugates
Kathleen N. Moore, MD
0.50 program credits
- Kathleen N. Moore, MD
0.50 program credits

22/11